Valuation: CS Diagnostics Corp.

Market Cap 2.12M 1.89M 1.76M 1.61M 3.03M 204M 3.06M 21.32M 8.26M 104M 7.98M 7.8M 335M P/E 2024
232,000x
P/E 2025 1,077x
Enterprise Value 2.12M 1.88M 1.76M 1.6M 3.02M 204M 3.05M 21.26M 8.24M 104M 7.95M 7.78M 334M EV / Sales 2024
1,357x
EV / Sales 2025 375x
Free-Float
14.55%
Yield 2024 *
-
Yield 2025 -
1 day-4.41%
1 week+664.71%
Current month+664.71%
1 month+124.14%
3 months+96.97%
6 months-51.77%
Current year-78.75%
1 week 0.01
Extreme 0.0085
0.06
1 month 0
Extreme 0.0005
0.06
Current year 0
Extreme 0.0005
0.4
1 year 0
Extreme 0.0005
0.4
3 years 0
Extreme 0.0005
5.64
5 years 0
Extreme 0.0005
8.5
10 years 0
Extreme 0.0005
28.95
Manager TitleAgeSince
Chief Executive Officer 56 2022-03-31
Director of Finance/CFO 47 2021-12-31
Corporate Officer/Principal 45 2024-07-17
Director TitleAgeSince
Chairman 56 1996-09-24
Director/Board Member 47 2021-12-31
Director/Board Member 54 2025-08-31
Date Insider Type Main position Quantity % Market Cap. Importance
12/31/25 Other

Chief Executive Officer

49,362,500 35.9418%
12/31/25 Other

Chief Executive Officer

104,507,800 76.0941%
12/31/25 Other

Chief Executive Officer

42,560,096 30.9888%
Change 5-day change 1-year change 3-year change Capi.($)
-4.41%+664.71%-80.18%-24.42% 2.12M
+0.84%-3.74%-26.69%+1.85% 167B
-0.07%-2.55%-9.53%+11.07% 111B
+0.90%+1.13%-24.83%+0.58% 105B
-1.24%-0.76%-49.04%-12.75% 74.82B
-0.24%+0.69%+0.16%+72.58% 59.11B
-0.86%+2.96%+13.57%+59.50% 51.8B
-0.71%-3.82%-7.72%-31.41% 48.5B
+0.12%-0.17%-18.21%+20.29% 40.79B
-1.01%-1.45%+28.48%-9.72% 32.54B
Average -0.67%-0.53%-17.40%+8.76% 69.02B
Weighted average by Cap. +0.02%-1.11%-16.32%+10.14%

Financials

2024 2025
Net sales 111K 98.54K 91.98K 83.83K 158K 10.66M 160K 1.11M 431K 5.45M 416K 407K 17.49M 204K 181K 169K 154K 291K 19.61M 294K 2.05M 793K 10.03M 766K 749K 32.18M
Net income 761 676.15 631.07 575.2 1.08K 73.16K 1.09K 7.64K 2.96K 37.4K 2.86K 2.8K 120K 71.22K 63.28K 59.06K 53.83K 102K 6.85M 102K 715K 277K 3.5M 267K 262K 11.23M
Net Debt -501 -445.14 -415.46 -378.68 -714.19 -48.16K -720.84 -5.03K -1.95K -24.62K -1.88K -1.84K -79.02K -6.81K -6.05K -5.65K -5.15K -9.71K -655K -9.8K -68.37K -26.49K -335K -25.58K -25.02K -1.07M
Logo CS Diagnostics Corp.
CS Diagnostics Corp is a Germany-based medical technology and distribution company. The Company is focused on developing and commercializing therapeutic and preventive solutions to improve patient care and outcomes. Its primary products are CS Protect-Hydrogel, a tissue spacer gel designed for use in radiation therapy, and MEDUSA, a surface disinfectant. CS Protect Hydrogel is an injectable organ spacer initially targeted for prostate cancer radiotherapy, where it increases the distance between the prostate tumor and the rectum to reduce radiation damage to healthy tissue. It is ready-to-use (pre-mixed in a sterile package) rather than requiring on-site mixing by clinicians. MEDUSA’s formulation provides an extended duration of antimicrobial protection on surfaces. It includes color-changing test strips that allow users to verify the concentration of the active ingredient over time.
Employees
1
Date Price Change Volume
26-09-30 US$0.008500 -.--% 1,000
  1. Stock Market
  2. Stocks
  3. CSDX Stock